Verrica Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview

Verrica Pharmaceuticals

04/08/2026 22:33

Verrica Pharmaceuticals Inc VRCA.OQ VRCA.O is expected to  show a fall in quarterly revenue when it reports  results on August 6 for the period ending June 30 2026
The West Chester Pennsylvania-based  company is expected to report a 54.9% decrease in revenue to $5.733 million from $12.7 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Verrica Pharmaceuticals Inc is for a loss of 38 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Verrica Pharmaceuticals Inc is $17.00, about 223.8% above its last closing price of $5.25
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.38
-0.36
-0.41
Missed
-12.9
Dec. 31 2026
-0.78
-0.79
-0.46
Beat
42.1
Sep. 30 2025
-0.67
-0.67
-0.03
Beat
95.6​
Jun. 30 2025
-0.70
-0.70
0.02
Beat
102.8
​​Mar. 31 2025
-1.05
-0.97
-1.00
Missed
-2.6
Dec. 31 2024
-2.84
-2.62
-2.40
Beat
8.6​
Sep. 30 2024
-3.93
-3.67
-4.90
Missed
-33.5
Jun. 30 2024
-4.28
-4.25
-3.70
Beat
12.9
This summary was machine generated August 4 at 21:33 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)